Hayden E. Klein

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual Scientific Session.

New findings may help patients with low to moderate risk of tumor lysis syndrome while reducing the burden for hematologists.

After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.

Panelists explored responsible, patient-centered use of artificial intelligence (AI) in cardiovascular care at the American College of Cardiology 2025 Annual Scientific Session.

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.

MACRO trial researchers said adapting to the COVID-19 pandemic mid-trial may have undercut the efficacy of the intervention, but it still showed promise.

Despite showing no overall benefit, an in-home paramedic visit appeared to help women avoid readmissions more than men.

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type 2 diabetes.

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Five abstracts showcase critical insights into women’s cardiovascular health, highlighting rising maternal mortality, elevated heart failure risk after ovary removal, and more.

New research suggests areas with higher concentrations of microplastics also have higher rates of chronic disease.

A real-world analysis showed a link between continuous glucose monitor (CGM) distribution channel and outcomes for patients with diabetes.

One study found that Black women were 3 times more likely to die of maternal deaths due to cardiovascular disease than White women.

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.

Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes.

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

Jorge García, PharmD, MS, MBA, MHA, highlights the need for infusion pharmacy optimization to sustain oncology care amid rising costs and evolving value-based reimbursement models.

Patients expressed concern that overreliance on artificial intelligence (AI) could lead to clinicians losing their skills, both medical and interpersonal.

Artificial intelligence (AI) is emerging as a tool that can improve patient outcomes and provider care efficiency, says Douglas Flora, MD, FACCC, of St. Elizabeth Healthcare.

Long-term effects of COVID-19 include lingering symptoms that take months to improve, more severe illness for cancer survivors, and a higher risk of death after infection for people living in rural areas.

A new report shows most Americans believe the government is too involved in health care regulation and want to see a ban on pharmaceutical company advertisements in the US.

Using artificial intelligence (AI) to help expedite processes for physicians can help them spend more face time with patients and stay up-to-date with the medical literature, says Douglas Flora, MD, FACCC.

Jorge García, PharmD, MS, MBA, MHA, discusses key takeaways from ACCC Capitol Hill Day and innovative strategies in pharmacy optimization.

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.

The Republican bill for the congressional budget narrowly passes the House of Representatives, advancing to the Senate floor.

Susan Escudier, MD, FACP, discusses the impact of insurance coverage gaps, transportation barriers, and financial hardships on cancer care access and emphasizes the need for payers to better support patients at high risk.

When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 and PD-L1 inhibitors.